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Dr RossM. Bremner (Phoenix, Ariz). I thank DrMauchley and
colleagues for providing me with a manuscript well in advance of
the meeting, but even more for providing me with a new and im-
proved manuscript just this morning. This manuscript contains all
their latest data, and it is a tribute to the Society that the opportunity
of presenting this work today has stimulated Dr Mauchley and col-
leagues to produce another set of fairly intricate experiments to
greatly add to this article. In fact, the manuscript is quite impressive.
The group has previously, as we were reminded this morning,
taught us that this enzyme, sPLA2, is important in reflux disease.
This morning they have answered a question regarding whether
this enzyme is also important in mature adenocarcinoma cells.
The study was clearly planned and expertly performed, but I do
have a few questions. The first question regards the specificity ofThe Journal of Thoracic and Cathe inhibitor. Dr Mauchley, how have you convinced yourselves
that the inhibitor is working at the doses you used by looking at
downstream indicators such as LOX or COX activity or leukotriene
or prostaglandin production?
Dr Mauchley. First, I thank you for your comments. To answer
your first question, this inhibitor was developed by a group in
Australia. According to 2 of their initial publications, they deter-
mined that it was a group IIA–specific inhibitor by testing it against
human recombinant group IIA sPLA2 as well as a few of the other
isoforms.
With respect to looking at downstream players in the whole
sPLA2 signal transduction pathway, we have not done that yet, al-
though we plan to do so. In particular, I think that it is important to
look at PGE2 and leukotriene B4 production. We have collaborated
with a lipid group at the university that does mass spectrometry to
help us look into this.
Dr Bremner. I think that will be important. The studies showed
that the inhibition of sPLA2 decreased the number of viable cells in
your cultures. Do you think that this is really a proapoptotic effect,
or do you think that this is cell cycle arrest?
DrMauchley. That is a good question. So far, most of our work
in this area has been to assess proliferation; however, we do have
some early preliminary results with the FLO-1 cells that indicate
that this is more a proliferative process and less of an apoptotic pro-
cess. We used flow cytometry to try to stain for apoptotic cells
treated in a similar fashion and found very little difference.
Dr Bremner. This latest set of experiments that you did trans-
fecting cells with sPLA2 and then having a group of experiments
with knockdown of sPLA2 was very interesting. In your knock-
down group, though, I was surprised that you showed only a modest
reduction in cell proliferation, about 15%. Did you consider this
disappointing? Because it seems that blocking sPLA2 is not really
essential for cell proliferation, have you considered adding a se-
quential downstream inhibitor, such as a LOX or COX-2 inhibitor,
to see what the effect would be?
DrMauchley. First, I was not discouraged at all by the findings.
Although we showed efficient transfection with the GFP-contain-
ing construct, it was impossible to know whether transfection
was as efficient with the PLA2G2A construct. This could explain
the modesty of the reduction.
With respect to using other inhibitors, we have talked about that
in the past. We have experiments planned but have not conducted
any at this point.
DrBremner. Finally, your studies really sidestep the question of
how this inhibitor would work in an animal system. Is this inhibitor
toxic at all, and do you plan animal experiments to see how it works
on a tumor model in a mouse, for example?
Dr Mauchley. Yes, we are in the process of getting a protocol
amendment approved so that we can inject these cells into nude
mice subcutaneously and assess their growth. The inhibitor that
we use is actually orally bioavailable, and in some of our previous
work we were able to get significant inhibition in vivo by gavage-
feeding mice with the inhibitor. We are planning on feeding the in-
hibitor to mice to see whether we can attenuate growth in vivo as
well as to use the transfected cell lines to see whether we can get
increased growth with overexpression.
Dr Bremner. Fascinating work. Thank you very much.rdiovascular Surgery c Volume 139, Number 3 599
